Prognostic Significance of the Loss of Heterozygosity of in Early-Stage Lung Adenocarcinoma.

Lung cancer is a common disease with a poor prognosis. Genomic alterations involving the gene are common in lung carcinomas, although much is unknown about how different mutations, deletions, and expressions influence the disease course. The first approval of a -directed inhibitor was recently approved by the FDA. Mutations in the gene have been associated with poor prognosis for lung adenocarcinomas, but implications of the loss of heterozygosity (LOH) of have not been investigated. In this study, we have assessed the LOH of in early-stage lung adenocarcinoma by analyzing DNA copy number profiles and have investigated the effect on patient outcome in association with mRNA expression and somatic hotspot mutations. mutation was present in 36% of cases and was associated with elevated mRNA expression. LOH in was associated with a favorable prognosis, more prominently in mutated than in wild-type patients. The presence of both LOH and mutation in conferred a better prognosis than mutation alone. For wild-type tumors, no difference in prognosis was observed between patients with and without LOH in . Our study indicates that LOH in is an independent prognostic factor that may refine the existing prognostic groups of lung adenocarcinomas.